Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Large B-Cell, Diffuse 1Leukemia 1Hodgkin Disease 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Adenocarcinoma Of Esophagus 1

Interventions

Cyclophosphamide 82fludarabine phosphate 68Mycophenolic Acid 59Whole-Body Irradiation 52Peripheral Blood Stem Cell Transplantation 51Tacrolimus 49Melphalan 44Etoposide 42Busulfan 39fludarabine 36Rituximab 36Filgrastim 36Granulocyte Colony-Stimulating Factor 35Brentuximab Vedotin 33Cyclosporine 32Doxorubicin 28Methotrexate 27Antilymphocyte Serum 27Radiotherapy 24Dacarbazine 19Vinblastine 18Nivolumab 18Cytarabine 18Prednisone 16Carmustine 16thymoglobulin 15Stem Cell Transplantation 15Sirolimus 15Alemtuzumab 14Vincristine 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Hodgkin Disease × pegylated granulocyte colony-stimulating factor, human × Clear all
NCT01169636 2021-01-06

Panobinostat Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Compared With ICE For Relapsed Hodgkin Lymphoma

M.D. Anderson Cancer Center

Phase 1/2 Completed
62 enrolled 13 charts
Lymphoid

Hodgkin Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡